Seattle Children’s On the Pulse reports the hospital’s research teams are advancing the ways hospitals treat pediatric cancer patients with CAR T-cell immunotherapies. For the youngest patients — between 1 and 3 years old — Seattle Children’s physician Colleen Annesley, MD, reports that CAR T-cell therapy is safe and effective in a paper presented in December at the 2019 American Society of Hematology annual meeting. For older patients experiencing the systemic inflammatory response cytokine release syndrome (CRS) as a side effect of CAR T-cell therapy, doctors at Seattle Children’s have found that treating mild CRS promptly instead of waiting does not reduce the persistence of CAR T-cells in the body, but does reduce by half the rate of severe CRS. The finding is likely to change the practices of other pediatric cancer centers using CAR T-cell immunotherapies.

Read Fine-Tuning CAR T-Cell Immunotherapy to Benefit More Kids, in On the Pulse, Dec. 11, 2019

Read Great News: CAR T-Cells Are Effective and Safe in Babies, Medscape Medical News, Dec. 9, 2019.

Related article in Medscape: Novel Booster Infusions Reactivate CAR-T Cells, Prevent Relapse, Dec. 16, 2019.